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Abstract: Testosterone is more than a “male sex hormone”. It is an important contributor to 
the robust metabolic functioning of multiple bodily systems. The abuse of anabolic steroids by 
athletes over the years has been one of the major detractors from the investigation and treatment 
of clinical states that could be caused by or related to male hypogonadism. The unwarranted 
fear that testosterone therapy would induce prostate cancer has also deterred physicians form 
pursuing more aggressively the possibility of hypogonadism in symptomatic male patients. 
In addition to these two mythologies, many physicians believe that testosterone is bad for 
the male heart. The classical anabolic agents, 17-alkylated steroids, are, indeed, potentially 
harmful to the liver, to insulin action to lipid metabolism. These substances, however, are not 
testosterone, which has none of these adverse effects. The current evidence, in fact, strongly 
suggests that testosterone may be cardioprotective. There is virtually no evidence to implicate 
testosterone as a cause of prostate cancer. It may exacerbate an existing prostate cancer, although 
the evidence is ﬂ  imsy, but it does not likely cause the cancer in the ﬁ  rst place. Testosterone 
has stimulatory effects on bones, muscles, erythropoietin, libido, mood and cognition centres 
in the brain, penile erection. It is reduced in metabolic syndrome and diabetes and therapy 
with testosterone in these conditions may provide amelioration by lowering LDL cholesterol, 
blood sugar, glycated hemoglobin and insulin resistance. The best measure is bio-available 
testosterone which is the fraction of testosterone not bound to sex hormone binding globulin. 
Several forms of testosterone administration are available making compliance much less of an 
issue with testosterone replacement therapy.
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As we age, the body undergoes multiple degenerative changes at multiple sites and in 
multiple systems. The changes of aging are inevitable and inexorable and represent 
the march toward ultimate death. We are mortal beings whose destiny it is to die. As 
we come to learn about the processes of life we can better prepare ourselves for the 
ﬁ  nality of death and on the way perhaps retard the degenerative process, or repair it 
(for however long we may enjoy this repair), or substitute chemical compounds that 
our bodies once produced in abundance, an abundance which fades with the advance 
of age.
Among the changes which occur with aging are those that affect several aspects 
of the endocrine system which reduces its secretions to varying degrees in different 
individuals. These reductions in secretions are identiﬁ  ed by a poor but widely recog-
nized appellation, the “pauses”: menopause (decreased ovarian function), adrenopause 
(decreased adrenal function, especially with regard to dehydroepiandrosterone secre-
tion), somatopause (decreased growth hormone production), andropause (decreased 
hypothalamic-pituitary testicular function with diminished testosterone availability 
and impaired spermatogenesis) (Lamberts 1997).
No one will argue with the well-established fact that the dramatic lows of testos-
terone as seen in castration or other signiﬁ  cant primary testicular disturbances such 
as those induced by chemotherapy, radiation therapy, congenital problems, or as seen Clinical Interventions in Aging 2007:2(4) 568
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in secondary testicular insufﬁ  ciency (eg, large compressive 
pituitary or hypothalamic tumors) produce dramatic signs 
and symptoms of testosterone deﬁ  ciency that require tes-
tosterone replacement therapy. Less clear, or at least more 
controversial, is the necessity of treating the gentler reduction 
of testosterone seen in the aging process.
That testosterone decreases with age has been clearly 
established by many studies over many years in several dif-
ferent populations of men (Harman et al 2001; Feldman et al 
2002; Araujo et al 2004; Kaufman and Vermeulen 2005). 
Of even greater signiﬁ  cance is the steeper fall of the most 
biologically active fraction of total testosterone, non-sex 
hormone binding globulin (SHBG)- bound testosterone, 
or bioavailable testosterone (bio-T). The classical, but not 
the only approach to measuring bio-T, is to precipitate out 
SHBG (and hence the testosterone which is strongly bound 
to it as well) and measure the remainder as total testosterone 
(Tremblay 2003). Vermeulen et al (1999) have devised a less 
tedious and less expensive method of measuring a surrogate 
for bio-T, namely calculated bio-T, inserting total T, albumin, 
SHBG and a constant into a mathematical formulation. There 
is a strong correlation between actual bio-T and calculated 
bio-T (Emadi-Konjin et al 2003).
Does the diminution that age brings with it in both total 
and bioavailable T have any clinical signiﬁ  cance? This 
question leads us to the theme of this paper, “The Many 
Faces of Testosterone”. If testosterone were simply a “sex 
hormone” involved only with sexual desire and arousal we 
might tend to dismiss testosterone treatment in the aging 
man as merely a “life-style” therapy without any substan-
tive basis for broad physiological necessity. The fact is, 
however, that the sexual attributes of testosterone are the 
least of its physiological necessities and that testoster-
one has a broad spectrum of demonstrated physiological 
functions as well as a wide variety of physiological and 
pathophysiological associations about which we are just 
learning.
The many faces of testosterone
Testosterone is everywhere playing multiple roles from 
intrauterine life to advanced age. Table 1, the contents of 
which are always undergoing change primarily because of 
newly observed associations, provides an overview of the 
bodily systemic functions and patho-physiological states 
in which testosterone ﬁ  nds itself implicated. In some of 
these states there is a clear physiological cause and effect 
relationship. In others, evidence of the physiological role is 
early or tenuous.
Intrauterine life in a 46 XY fetus
A 46 XY fetus is destined to become a male because the 
Y chromosome carries testicular determining gene which 
initiates transformation of the undifferentiated gonad into 
testes (Töhönen 2003). The testes subsequently produce 
both Mullerian Inhibiting Factor (to induce degeneration of 
the Mullerian system, the internal female ductal apparatus) 
and testosterone (to stimulate growth and development of 
the Wolfﬁ  an system – epididymus, vas deferens, seminal 
vesicle and, after conversion to dihydrotestosterone (DHT) 
by the enzyme 5-α-reducase, the prostate gland). DHT is 
also the primary androgen to cause androgenization of the 
external genitalia.
If in a 46 XY individual testosterone is either not pro-
duced in adequate concentrations as in gonadal dysgenesis 
(MacLaughlin and Donahue 2004), or in the absence of 
the enzyme 17 alpha-hydroxylase so that testosterone is 
not produced (Ergun-Longmire et al 2006), or testosterone 
androgen receptors are absent as in the androgen insensitiv-
ity syndrome (Hughes and Deeb 2006), phenotypic females 
will result.
Puberty
Puberty occurs when there is an “awakening” of the 
hypothalamic-pituitary axis. The hypothalamus increases 
its secretion of gonadotropin releasing hormone (GnRH) 
which in turn stimulates the release of luteinizing hormone 
(LH) and follicle stimulating hormone (FSH). This leads 
to a signiﬁ  cant increase in the production of testicular tes-
tosterone and the induction of the well-known secondary 
Table 1 The many faces of testosterone
1.  Intrauterine life in a 46XY fetus
2. Puberty
3. Classical  hypogonadism
4. Post-menopausal  women
5. Bones
6. Muscles/frailty
7. Libido
8. Erectile  function
9. Cognition
10. Mood
11.  Erythropoiesis and anemia
12.  Coronary artery disease
13. Obesity
14. Diabetes  mellitus
15. HIV  AIDS
16. Autoimmune  Disease
17. Narcotic  dependence
18. Age-related  hypogonadismClinical Interventions in Aging 2007:2(4) 569
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sex characteristics associated with puberty: growth spurt, 
increased libido, increased erectile function, acne, increased 
body hair, increased muscle mass, deepening of the voice, 
spermatogenesis, gynecomastia (usually transient).
Classical hypogonadism
Testosterone treatment is unequivocally needed in classical 
hypogonadism for reasons discussed in subsequent subsec-
tions. In classical hypogonadism, testosterone production is 
usually clearly below the lower limit of normal and patients 
are highly symptomatic; the various symptoms are easily 
related to the deﬁ  ciencies in various bodily systems where 
testosterone action is important. Symptoms of testosterone 
deﬁ  ciency are listed in Table 2. A few prominent causes of 
classical hypogonadism are listed in Table 3.
Post-menopausal women
With the decline of ovarian function in menopause, not 
only do estrogen levels decline, but so does testosterone 
availability, since the ovaries contribute, either by direct 
secretion or through precursor production, about 50 percent 
of circulating testosterone. The other 50 percent is supplied 
by the adrenal glands. Many post-menopausal or oopho-
rectomized women are symptomatic as a consequence of 
reduced testosterone, the leading symptom being loss of 
libido (Sherwin and Gelfand 1987; Simon et al 2005). There 
is an increasing trend toward testosterone supplementation in 
these women. Such supplementation may also lead, not only 
to increased libido, but to increased bone mineral density 
and an improvement in general overall sense of well-being 
including energy, strength, motivation and mood (Davis et al 
1995; Davis et al 2000).
Bones
Testosterone has two major effects on bones: (a) through 
conversion to estradiol by way of the enzyme, aromatase, tes-
tosterone inhibits osteoclastic activity and hence bone resorp-
tion; and (b) through conversion to DHT via 5-α-reductase, 
it stimulates osteoblastic activity and so enhances the laying 
down of bone (Tivesten et al 2004; Davey and Morris 2005). 
Hypogonadal men are at risk for the development of osteope-
nia or osteoporosis and hence for subsequent fracture (Fink 
et al 2006). About one-third of all osteoporotic hip fractures 
occur in men and the risk of any osteoporotic fracture in men 
over 50 is as high as 25 percent (Seeman 1997; Adler 2006). 
Although treatment with testosterone in hypogonadal men 
increases bone mineral density (Katznelson et al 1996), it 
has not yet been established that this results in a reduction 
in fracture rate.
Muscles/frailty
Testosterone retains nitrogen and is an essential ingredient 
in the development and maintenance of muscle mass 
(Sinha-Hikim et al 2006). With a diminution in testosterone, 
muscle mass diminishes as does strength. Weakness and 
fatigue result. A number of studies have demonstrated the 
ability of testosterone to restore lean body mass (muscle) in 
hypogonadal men, while at the same time causing a reduction 
in fat mass (Wang et al 2004). Treatment of hypogonadal men 
with testosterone results in improvement in overall physical 
performance as well as strength as assessed by, eg, hand grip 
power (Page 2005). Because of decreased muscle strength 
and impaired balance, older hypogonadal men are suscep-
tible to falling and since they may already be osteopenic or 
Table 2 Symptoms or ﬁ  ndings of low testosterone
Weakness
Fatigue
Lethargy
Mood changes – dysthymia
 –  depression
 –  irritability
Decreased libido
Decreased erectile function
Decreased quality of orgasm
Decreased muscle mass
Decreased motivation
Loss of self-conﬁ  dence
Decreased energy
Anemia
Osteopenia/osteoporosis
Decreased facial, axillary, pubic hair
Insomnia 
Flushes
Table 3 Selected causes of classical hypogonadism
A.  Primary Hypogonadism (Testicular Causes – High LH and FSH)
 Castration
 Testicular  trauma
 Klinefelter’s  Syndrome
 Orchitis
 Chemotherapy
  Radiation therapy to the testes
B.   Secondary Hypogonadism (Hypothalamic-Pituitary Causes-Low LH 
and FSH)
 GnRH  insufﬁ  ciency (idiopathic or Kallmann’s syndrome)
  Pituitary or hypothalamic tumour
 Hyperprolactinemia
 Pituitary  surgeryClinical Interventions in Aging 2007:2(4) 570
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osteoporotic as a consequence of hypogonadism, they are at 
increased risk for fracture as a result of the fall (Szulc et al 
2003). Men with low levels of testosterone as in androgen 
deprivation therapy for prostate cancer, have a signiﬁ  cant 
decrease in lean body mass and hemoglobin, while at the 
same time they experience an increase in weight, body fat 
and body mass index (Smith et al 2002). Treatment of frail 
hypogonadal men with testosterone, therefore, can result 
in changes in muscle gene expression, increased muscle 
mass, improvements in strength, power and endurance and 
improved physical function.
Libido
Testosterone has several positive effects on sexual function, 
but its most signiﬁ  cant effect is on libido, sexual interest and 
arousal. Boys going through puberty develop an enhanced 
interest in sex (thoughts, fantasies, masturbation, inter-
course) as a consequence of rising levels of testosterone. 
Hypogonadal men usually have a signiﬁ  cant improvement 
in libido when TRT is initiated (Wang et al 2000; Morley 
and Perry 2003).
Erectile function
Testosterone does play a minor role in generation of erections 
(Mills et al 1992) but its impact upon erections can often be 
seen in hypogonadal men who do not respond to sildenaﬁ  l 
citrate until testosterone is added to the therapeutic regimen 
(Kalinchenko et al 2003; Rosenthal et al 2006).
Testosterone makes a contribution to nitric oxide forma-
tion. Nitric oxide, released from penile nerves stimulates 
guanylate cyclase which catalyzes the transformation of 
guanosine-5-triphosphate into 3’,5’-cyclic, guanosine 
monophosphate (cyclic GMP). Gyclic GMP causes vasodi-
latation and hence erection formation (Morelli et al 2005). 
The breakdown of cyclic GMP to GMP is mediated by the 
enzyme, phosphodiesterase type-5, the inhibitors of which 
(eg, sildenaﬁ  l citrate) enhance erection formation and main-
tanence (Carson and Lue 2005).
Cognition
Testosterone functions within the brain. There are several 
lines of evidence for this: there are androgen receptors within 
the brain; testosterone is converted to both dihydrotestos-
terone (DHT) and estradiol by the actions of 5-α-reductase 
and aromatase respectively in the brain; steroid hormones 
promote neuronal cell growth and survival (Azad et al 2003). 
Testosterone enhances cerebral perfusion in hypogonadal 
men and that perfusion takes place speciﬁ  cally in Brodman 
areas 8 and 24, regions of the brain that are concerned with: 
strategic planning, higher motor action, cognitive behaviors, 
emotional behavior, generalized emotional reaction, wakeful-
ness and memory (Greenlee 2000; Azad et al 2003). Studies 
of cognition demonstrate that older men with higher levels of 
free testosterone index (a surrogate measure of bioavailable 
testosterone) have better scores in tests of: visual memory, 
verbal memory, visuospatial functions and visuomotor 
scanning. Hypogonadal men have lower scores in tests of 
memory, visuospatial function, with a faster decline in visual 
memory (Moffat et al 2002). In a very small, short term 
placebo-controlled study hypogonadal men with Alzheimer’s 
Disease (AD) treated with testosterone demonstrated a 
modest improvement in a cognition assessment score in AD 
(Tan and Pu 2003).
Both men and women with Alzheimer’s Disease were 
found to have an increased concentration of SHBG and 
decreased free androgen index when compared with controls 
(Paoletti et al 2004). In a prospective study of 574 men whose 
baseline age span was 32–87 years and who were followed 
for a mean of 19.1 years (range, 4–37), the risk of developing 
Alzheimers’ Disease decreased 26 percent for each 10 unit 
increase in free testosterone index. The authors concluded 
that testosterone may be important for the prevention and 
treatment of AD (Moffat et al 2004).
Mood
Many studies demonstrate an improvement in mood of 
hypogonadal men treated with testosterone (Wang et al 1996; 
Azad et al 2003). The relationship between testosterone 
status and mood, particularly depression, remains unresolved. 
Using Beck’s Depression Inventory, Barrett-Connor and 
colleagues found that the depression score worsened as men 
aged, exactly at a time when testosterone levels are decreas-
ing (Barrett-Connor et al 1999). Pope and colleagues found 
that testosterone treatment in men with refractory depression 
lowered the Hamilton Depression rating scale and the Clini-
cal Global Impression severity rating (Pope et al 2003). The 
Beck Depression Inventory remained unchanged in Pope’s 
study.
That there is an association between depression and 
testosterone concentration seems possible because of the 
observation that depression may be associated with reduced 
testosterone concentrations, hypogonadal men may have 
their symptoms of depression relieved by TRT and that tes-
tosterone itself may have anti-depressant properties (Pope 
et al 2003). The evidence, however, is inconsistent. Seidman 
and colleagues (2002), for example, found that there was Clinical Interventions in Aging 2007:2(4) 571
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no relationship between testosterone and depression but 
there was an association of testosterone with dysthymia. 
McIntyre and colleagues (2006), on the other hand, found 
that middle-aged men with depression did have a reduction 
in bio-available testosterone.
Erythropoiesis and anemia
Testosterone is a stimulant of hematopoiesis in the bone 
marrow and consequently, increases the hematocrit (Shahidi 
1973). Men with unexplained anemia should have their 
testosterone measured and if reduced, these men should 
be treated with testosterone. Because of the erythropoietin 
stimulating effect of testosterone, one of the parameters to 
be monitored during testosterone treatment is hematocrit 
since a small percent of testosterone-treated men develop 
polycythemia.
Bhatia et al (2006) studied 70 male patients with type2 
diabetes mellitus (age range 24–78 years). Thirty-seven sub-
jects were found to have hypogonadism based on a calculated 
free testosterone level of less than 6.5 μg/dl. The hypogonadal 
group had a statistically signiﬁ  cant lower hematocrit. Anemia 
was observed in 23% of the patients (16 out of 70). In 14 of 
15 anemic patients calculated free testosterone was low.
Coronary artery disease
Before the ready availability of non-injectible testosterone 
preparations, and because of their ease of administration 
by the oral route, 17-alkylated steroids were popular sur-
rogate agents for testosterone. These substances, however, 
were capable of inducing several risk factors for coronary 
artery disease (Kopera 1993; Hall and Hall 2005) and as a 
consequence, particularly after the revelations of extensive 
17-alkylated anabolic steroid abuse by athletes, testosterone, 
became unjustly incriminated. The evidence, however, tends 
to suggest just the opposite; testosterone may even be car-
dioprotective. Dunajska and colleagues have demonstrated 
that when compared to controls, men with coronary artery 
disease tend to have: lower total testosterone levels and free 
androgen indices, more abdominal fat, higher blood sugar 
and insulin levels (Dunajska et al 2004).
Intracoronary artery infusion of testosterone causes 
signiﬁ  cant coronary artery dilatation and not constriction 
as previously thought (Webb et al 1999). When degree of 
coronary obstruction is assessed by angiography, there is a 
direct relationship between degree of coronary artery nar-
rowing and reduced testosterone levels (Phillips et al 1994). 
Men with low testosterone levels have been observed to have: 
premature atherosclerosis, increased visceral adipose tissue, 
hyperinsulinemia, and other risk factors for myocardial 
infarction (Phillips 2005). Insulin resistance has been shown 
to be associated with a decrease in Leydig cell secretion of 
testosterone (Pitteloud et al 2005). Muller and colleagues 
suggest that low endogenous total testosterone and SHBG 
levels increase the risk of metabolic syndrome in aging and 
aged men. They demonstrated that low levels of testosterone 
are related to lower insulin sensitivity and higher fasting insu-
lin levels (Muller et al 2005). These authors speculate that 
testosterone might play a protective role in the development 
of metabolic syndrome, insulin resistance, diabetes mellitus 
and cardiovascular disease in aging men.
Dobs and colleagues found that men with an increased 
body mass index had both reduced testosterone and reduced 
high density lipoprotein (HDL) levels. Treatment with tes-
tosterone increased the levels of HDL (Dobs et al 2001). 
Rising levels of HDL are not a consistent ﬁ  nding with TRT. 
More often, however, one ﬁ  nds reduced total cholesterol, low 
density lipoprotein (LDL) cholesterol and triglyceride levels 
with TRT (Zgliczynski et al 1996; Whitsel et al 2001).
Smith and colleagues (2005) undertook a prospective 
study on the contribution of stress to coronary heart dis-
ease. Their study, which involved 2512 men aged 45 to 
59 years, looked at a number of metabolic parameters. They 
found that an increased cortisol to testosterone ratio was 
associated with a high risk of coronary artery disease and 
that this risk was mediated by components of the insulin 
resistance syndrome. They reported that high cortisol and 
low testosterone levels are associated with a worsening 
of insulin resistance and that there is evidence to support 
the possibility of improving this pattern by treatment with 
testosterone.
Diabetes mellitus, obesity, 
metabolic syndrome
The deﬁ  nition of the metabolic syndrome continues to be a 
work in progress. Within the last decade a number of deﬁ  ni-
tions have emerged each with its own set of criteria although 
there is considerable overlap among them. The most recent 
deﬁ  nition seems to enjoy considerable consensus. It requires 
central adiposity (94 cm waist circumference) plus two 
of, increased triglycerides, decreased HDL cholesterol, 
hypertension, insulin resistance as evidenced by impaired 
glucose tolerance, or frank diabetes (Alberti 2005). Almost 
immediately on the heels of this consensus, came a number 
of speciﬁ  c chemical markers which have been proposed to 
complement the basic deﬁ  nition of the metabolic syndrome 
(Eckel et al 2005).Clinical Interventions in Aging 2007:2(4) 572
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Adipose tissue contains high concentrations of aromatase 
thus accelerating the conversion of testosterone to estradiol 
(Wake et al 2007). Estradiol, in turn, suppresses gonado-
tropin secretion which reduces the output of testosterone 
(Chongthammakun and Terasawa 1993). Diabetes mellitus 
is associated with decreased levels of testosterone.
Individuals with metabolic syndrome are at increased risk 
for developing coronary artery disease and diabetes mellitus. 
Predicting who might develop the metabolic syndrome would 
allow preventive measures to be taken in addition to weight 
control and other lifestyle modiﬁ  cations such as cessation 
of smoking and increased exercise. It is known that with 
decreasing testosterone availability in aging males there is an 
increase in fat mass and decrease in lean body mass (van den 
Beld et al 2000), there are disorders of insulin and glucose 
metabolism (Haffner et al 1996) and dyslipidemia (Tsai et al 
2004). Kupelian and colleagues (2006) in analyzing data from 
the Massachusetts Male Aging Study demonstrated that men 
with low levels of testosterone, sex hormone-binding globu-
lin, or clinical androgen deﬁ  ciency, especially men with a 
BMI of greater than 25, were at increased risk of developing 
the metabolic syndrome and hence, diabetes mellitus and/or 
coronary artery disease.
It is now well-established that elderly men with type 
2 diabetes mellitus have reduced levels of testosterone 
(Barrett-Connor 1992; Betancourt-Albrecht and Cunningham 
2003). It is known, however, that obese men and diabetic 
men have reduced levels of SHBG (Barrett-Connor 1990) 
which could account for the lower total testosterone levels 
found in diabetic men. Dhindsa et al (2004) studied 103 male 
patients who had type 2 diabetes mellitus using free tes-
tosterone (done by equilibrium dialysis) or calculated free 
testosterone which takes SHBG levels into account. Of the 
103 patients, 57 had free testosterone by equilibrium dialysis 
and of these, 14 (25%) had a free T below 0.174 nmol/L 
and were considered hypogonadal. Using a total testoster-
one of 10.4 nmol/L (300ng/dl) as the lower limit of normal 
45 patients (43%) were in the hypogonadal range. They also 
found that LH and FSH concentrations were signiﬁ  cantly 
lower in the hypogonadal group. The authors thus concluded 
that hypogonadotropic hypogonadism was a common ﬁ  nding 
in type 2 diabetes irrespective of glycemic control, duration 
of disease or the presence of complications of diabetes or 
obesity.
The ﬁ  nding of hypogonadism in diabetic men is not just 
a scientiﬁ  c curiosity, it may have practical management 
implications. Kapoor and colleagues (2006) undertook a 
placebo-controlled double blind study to determine the effect 
of testosterone therapy on insulin resistance and glycemic 
control in hypogonadal men with type 2 diabetes. They found 
that men treated with testosterone had reductions in glycated 
hemoglobin insulin resistance, fasting blood sugar, waist 
circumference, waist/hip ratio and total cholesterol.
Autoimmune disease
There is an increased incidence of hypogonadism in men 
with rheumatoid arthritis. Tengstrand et al (2002) studied 
hormonal levels in 104 men with rheumatoid arthritis and 99 
age-matched healthy men. They divided their subjects into 
3 age groups: 30–49, 40–59, 60–69. Mean non-sex hormone 
binding globulin-bound testosterone (bioavailable testos-
terone) was lower in men with rheumatoid arthritis for each 
of the three groups. LH was also found to be lower in the 
patients with rheumatoid arthritis suggesting a hypothalamic-
pituitary cause of the reduced bioavailable testosterone. Of 
the 104 men with rheumatoid arthritis, 33 had hypogonadism 
compared to 7 of the 99 healthy controls.
The converse is also true; there is an increased incidence 
of rheumatic/autoimmune disease in men with hypogonadism. 
Jimenez-Balderas et al (2001) carried out neuroendocrine, 
genetic and rheumatologic investigations in hypogonadal 
men. Of the 13 hypogonadal patients, 8 (61%) had rheumatic 
autoimmune disease (ankylosing spondylitis, systemic lupus 
erythemetosus, rheumatoid arthritis, dermatomyositis). There 
is a low frequency of those diseases (0.83%) in the general 
population.
Decreased testosterone production in men with rheuma-
toid arthritis is a common ﬁ  nding (Stafford et al 2000), and it 
is now generally recognized that androgens have the capacity 
to suppress both the hormonal and cellular immune response 
and so act as one of the body’s natural anti-inﬂ  ammatory 
agents (Cutolo et al 2002). This known anti-inﬂ  ammatory 
action of testosterone has led to studying the effect of tes-
tosterone therapy in men with rheumatoid disease. Although 
not all studies have reported positive effects of testosterone 
treatment (Hall et al 1996), some studies do demonstrate an 
improvement in both clinical and chemical markers of the 
immune response (Cutolo et al 1991; Cutolo 2000). This 
observation would go along with more recent evidence that 
testosterone or its metabolites protects immunity by preserv-
ing the number of regulatory T cells and the activation of 
CD8+ T cells (Page et al 2006).
Narcotic dependence
Opioid substances are in common use both licit and illicit. 
Opiates are potent analgesics but they are also highly Clinical Interventions in Aging 2007:2(4) 573
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addictive. They are frequently prescribed for both acute and 
chronic pain and when used chronically, often induce opiate 
dependence in the user. Pain clinics regularly use narcotic 
agents in many of their patients. Methadone, in particular, 
is regularly prescribed to opiate addicts who have entered a 
program aimed at reducing narcotic dosage and ultimately 
weaning the patient off it altogether. Most men who are on 
chronic high doses of an opiate become hypogonadal. This 
was ﬁ  rst recognized in the 1970’s when heroin addicts were 
found to have suppressed levels of testosterone (Brambilla 
et al 1977). Also suppressed were LH and FSH pointing to 
a probable inhibition of GnRH release.
Since then there have been many publications document-
ing suppressed testosterone and gonadotropins (Daniell 2006) 
in men using opioid medications whether these agents were 
administrated orally (Daniell 2002) or intrathecally (Finch 
et al 2000). Not only do opioids act centrally by suppress-
ing GnRH, they also act directly on the testes inhibiting the 
release of testosterone by Leydig cells during stimulation 
with human chorionic gonadotropin (Purohit et al 1978). 
Although the large majority of men (and women) receiving 
opioids do develop hypogonadism, about 15 percent also 
develop central hypocorticism and 15 percent develop growth 
hormone deﬁ  ciency (Abs et al 2000).
HIV/AIDS
Testosterone insufﬁ  ciency has been associated with HIV 
infection in men (Dobs et al 1988). Early reports suggested 
that testosterone therapy may have an ameliorating effect 
on both depression and decreased energy in HIV infected 
men, even if testosterone levels were not reduced (Rabkin 
et al 1999; Grinspoon et al 2000; Rabkin et al 2000). Both 
depression and fatigue, however, are common features of HIV-
positive men and may be associated with factors other than 
reduced levels of testosterone. The disease itself may induce 
depression and fatigue may be a consequence of the disease, 
per se, or of some of the medications used to control HIV.
Because of inconclusive or conﬂ  icting results of testos-
terone treatment studies reported in the literature, Rabkin 
and colleagues (2004) undertook a comparison study among 
testosterone, the anti-depressant, ﬂ  uoxetine, and placebo 
in eugonadal HIV positive men. They found that neither 
ﬂ  uoxetine nor testosterone were different from placebo in 
reducing depression, but that testosterone did have a statisti-
cally signiﬁ  cant effect in reducing fatigue. It is note-worthy 
that fatigue was reduced with testosterone treatment even 
though virtually all the men in the study had testosterone 
levels within the reference range.
The message emanating from these accumulated studies 
is that HIV-infected men should have their testosterone levels 
measured and even if normal, a trial of testosterone treatment 
may be warranted in symptomatic men.
Hypogonadism in the aging male
As already indicated previously, testosterone levels, par-
ticularly bioavailable testosterone, fall with advancing age. 
This decline in testosterone availability may start to occur 
early in the forth decade but it usually becomes clinically 
manifest in the 50s and 60s. Although there is continuing 
debate about the best way to diagnose hypogonadism in 
the aging male, there appears to be a general consensus 
that symptomatic men with reduced levels of testosterone 
should be given a trial of testosterone therapy if there is no 
contraindication to do so (Bain et al 2007).
The reasons for considering such therapy become evident 
from the many associations, indicated above, that reduced 
testosterone has with a variety of both physiological functions 
(bone metabolism, muscle mass, cognitive function, libido, 
erectile function) and pathophysiological states (metabolic 
syndrome, diabetes mellitus, obesity, insulin resistance, 
autoimmune disease). Although a deﬁ  nitive long-term, large 
scale placebo-controlled double-blind study of testosterone 
therapy in the aging male has not yet been carried out, mul-
tiple shorter-term trials have suggested improvement by 
testosterone with a resultant enhancement of muscle mass, 
bone density, libido, erectile function, mood, motivation and 
general sense of well-being.
There are valid concerns about the safety of long-term 
treatment with testosterone particularly with respect to the 
cardiovascular system and the potential for stimulating 
prostate cancer development. There are no convincing hard 
data, however, to support these concerns. If anything, the 
data strongly suggest that adequate testosterone availability 
is cardioprotective and coronary risk factors such as diabe-
tes, obesity and the metabolic syndrome are associated with 
reduced testosterone levels. It is certainly appropriate to avoid 
giving testosterone to men with prostate or breast cancer but 
it is not appropriate to accuse testosterone of inducing the 
development of de novo prostate cancers since evidence for 
this accusation is lacking (Wang et al 2004; Feneley and 
Carruthers 2006).
Conclusion
Testosterone is a hormone with multifaceted physiological 
functions and multiple associations with pathophysiological 
states. It is an important hormone in male reproductive and Clinical Interventions in Aging 2007:2(4) 574
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metabolic function from intrauterine life to old age. In severe 
or classical hypogonadal states there is little controversy 
about the need to administer testosterone by an intramuscular, 
oral or transdermal formulation. There is controversy about 
making the diagnosis in the less severe cases of hypogonad-
ism associated with the aging male but the current evidence 
suggests that this is efﬁ  cacious in appropriately selected men 
and that there is little if any risk in giving aging symptomatic 
hypogonadal men a 6 month trial of therapy to determine 
whether symptoms will improve.
Testosterone is not a panacea for prolonging youth by 
warding off the aging process. It may, however, provide 
the appropriately selected symptomatic male with reduced 
testosterone availability assistance in helping that man move 
more gracefully into the senior years of his life.
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